- You can view the full Regeneron Pharmaceuticals Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Regeneron Pharmaceuticals fell $6.14 (-1.9%) to $320.38 on heavy volume. Throughout the day, 2,016,395 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 803,700 shares. The stock ranged in price between $317.23-$331.64 after having opened the day at $326.00 as compared to the previous trading day's close of $326.52. Other companies within the Health Care sector that declined today were: Ventrus Biosciences ( VTUS), down 63.0%, OxiGene ( OXGN), down 24.6%, Galena Biopharma ( GALE), down 16.4% and Stemline Therapeutics ( STML), down 12.1%. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.6 billion and is part of the drugs industry. Shares are up 18.6% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.
